Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2470-2479
Published online before print October 6, 2005, doi: 10.1161/01.ATV.0000189309.05924.88
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
25/12/2470    most recent
01.ATV.0000189309.05924.88v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Oliver, J. J.
Right arrow Articles by Newby, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Oliver, J. J.
Right arrow Articles by Newby, D. E.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2005;25:2470.)
© 2005 American Heart Association, Inc.


Brief Reviews

Stimulated Tissue Plasminogen Activator Release as a Marker of Endothelial Function in Humans

James J. Oliver; David J. Webb; David E. Newby

From Centre for Cardiovascular Science (J.J.O., D.J.W., D.E.N.), University of Edinburgh, Edinburgh, UK.

Correspondence to Dr James J. Oliver, Clinical Pharmacology Unit and Research Centre, University of Edinburgh, Western General Hospital, Crewe Rd S, Edinburgh, EH4 2XU. E-mail James.Oliver{at}ed.ac.uk

Series Editor: William Haynes Previous Brief Reviews in this Series:

•Choudhury RP, Fuster V, Badimon JJ. Fisher EA, Fayad ZA. MRI and characterization of atherosclerotic plaque: emerging applications and molecular imaging. 2002;22:1065–1074.
•Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. 2003;23:168–175.
•Oliver JJ, Webb DJ. Noninvasive assessment of arterial stiffness and risk of atherosclerotic events. 2003;23:554–566.
•Madjid M, Zarrabi A, Litovsky S, Willerson JT, Casscells W. Finding vulnerable atherosclerotic plaques: is it worth the effort? 2004;24:1775–1782.
•Morrow JD. Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. 2005;25:279–286.
•Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. 2005;25:2043–2053.

The initiation, modulation, and resolution of thrombus associated with eroded or unstable coronary plaques are critically dependent on the efficacy of endogenous fibrinolysis. This is dependent on the cellular function of the surrounding endothelium and vascular wall. In particular, the acute release of tissue plasminogen activator from the endothelium makes an important contribution to the defense against intravascular thrombosis. Here, we describe the rationale and methodology for, and clinical relevance of, assessing acute endothelial tissue plasminogen activator release in humans. The investigation of endothelial fibrinolytic function has the potential to provide major new insights into the pathophysiology of cardiovascular disease, and to shape future therapeutic interventions.

Local release of tissue plasminogen activator from the endothelium is an important defense against intravascular thrombosis and can be assessed in vivo in humans. We describe the rationale and methodology for, and clinical relevance of, assessing acute endothelial tissue plasminogen activator release in humans.


Key Words: arterial thrombosis • endothelial function • endothelium • fibrinolysis • thrombosis




This article has been cited by other articles:


Home page
HypertensionHome page
C. Giannarelli, A. Virdis, F. De Negri, E. Duranti, A. Magagna, L. Ghiadoni, A. Salvetti, and S. Taddei
Tissue-Type Plasminogen Activator Release in Healthy Subjects and Hypertensive Patients: Relationship With {beta}-Adrenergic Receptors and the Nitric Oxide Pathway
Hypertension, August 1, 2008; 52(2): 314 - 321.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
N. N. Lang, I. J. Guthmundsdottir, N. A. Boon, C. A. Ludlam, K. A. Fox, and D. E. Newby
Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers smoking, thrombin, and vascular responses in vivo.
J. Am. Coll. Cardiol., July 1, 2008; 52(1): 33 - 39.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
I. J. Guthmundsdottir, N. N. Lang, N. A. Boon, C. A. Ludlam, D. J. Webb, K. A. Fox, and D. E. Newby
Role of the endothelium in the vascular effects of the thrombin receptor (protease-activated receptor type 1) in humans.
J. Am. Coll. Cardiol., May 6, 2008; 51(18): 1749 - 1756.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. Pretorius, G. P. van Guilder, R. J. Guzman, J. M. Luther, and N. J. Brown
17{beta}-Estradiol Increases Basal but Not Bradykinin-Stimulated Release of Active t-PA in Young Postmenopausal Women
Hypertension, April 1, 2008; 51(4): 1190 - 1196.
[Abstract] [Full Text] [PDF]


Home page
Exp PhysiolHome page
R. M. Wadsworth
Oxidative stress and the endothelium
Exp Physiol, January 1, 2008; 93(1): 155 - 157.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
S. D. Robinson, C. A. Ludlam, N. A. Boon, and D. E. Newby
Endothelial Fibrinolytic Capacity Predicts Future Adverse Cardiovascular Events in Patients With Coronary Heart Disease
Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1651 - 1656.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. Barac, U. Campia, and J. A. Panza
Methods for Evaluating Endothelial Function in Humans
Hypertension, April 1, 2007; 49(4): 748 - 760.
[Full Text] [PDF]


Home page
HypertensionHome page
C. Giannarelli, F. De Negri, A. Virdis, L. Ghiadoni, A. Cipriano, A. Magagna, S. Taddei, and A. Salvetti
Nitric Oxide Modulates Tissue Plasminogen Activator Release in Normotensive Subjects and Hypertensive Patients
Hypertension, April 1, 2007; 49(4): 878 - 884.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
N. J. Brown
Blood Pressure Reduction and Tissue-Type Plasminogen Activator Release
Hypertension, April 1, 2006; 47(4): 648 - 649.
[Full Text] [PDF]